BACKGROUND: Activating point mutation of the BRAF gene, the most common genetic alteration reported in papillary thyroid carcinomas (PTC), has been associated with poor prognostic characteristics. AIM: Our objective was to determine the frequency of BRAFV600E mutation in PTC tumor tissues from the period 1960-2007 and to correlate it with clinicopathological parameters. SUBJECTS AND METHODS: DNAs were extracted from 242 PTCs, 23 sporadic medullary carcinomas, one anaplastic carcinoma and 6 poorly differentiated carcinomas. The presence of BRAFV600E mutation was determined using single strand conformation polymorphism method and verified by direct sequencing. RESULTS: BRAFV600E mutation was detected in 81 of 242 PTCs (33.5%), in one of 6 poorly differentiated carcinomas (16.7%) and in anaplastic carcinoma. BRAFV600E mutation was much less frequent in the follicular variant compared to classical variant and mixed follicular- classical variant of PTCs (p=0.001). BRAFV600E mutation was significantly associated with presence of nodal metastasis (p=0.029), more advanced TNM stage (p=0.014) and recurrence of disease (p=0.008). The mutation correlated with a higher age at diagnosis (p=0.049) and with a greater tumor size (p=0.041). Multivariate analysis confirmed these findings. The prevalence of BRAFV600E mutation before 1986 was significantly lower than after it (p=0.008). CONCLUSIONS: Our data suggest that BRAFV600E mutation is associated with high-risk clinicopathological characteristics of PTC and worse prognosis of patients. The frequency of the mutation significantly varied during the observed period but rather because of the different age distribution of patients in particular periods than as a consequence of Chernobyl accident.

Department of Molecular Endocrinology Institute of Endocrinology Prague Czech Republic

Zobrazit více v PubMed

Nature. 1995 Jun 1;375(6530):365 PubMed

CA Cancer J Clin. 2005 Jul-Aug;55(4):242-58; quiz 261-2, 264 PubMed

Cancer Res. 1997 May 1;57(9):1690-4 PubMed

J Clin Endocrinol Metab. 2004 Oct;89(10):5175-80 PubMed

Oncogene. 2003 Sep 25;22(41):6455-7 PubMed

Biol Cell. 2001 Sep;93(1-2):53-62 PubMed

Cell. 2004 Mar 19;116(6):855-67 PubMed

Int J Cancer. 1999 Mar 15;80(6):842-7 PubMed

Nature. 1992 Sep 3;359(6390):21 PubMed

J Clin Invest. 2005 Jan;115(1):94-101 PubMed

Endocr J. 2009;56(1):89-97 PubMed

Anticancer Res. 2008 Jan-Feb;28(1A):305-8 PubMed

J Natl Cancer Inst. 2003 Apr 16;95(8):625-7 PubMed

Clin Endocrinol (Oxf). 2004 Aug;61(2):239-43 PubMed

J Clin Endocrinol Metab. 2003 Nov;88(11):5399-404 PubMed

Endocr Relat Cancer. 2006 Mar;13(1):257-69 PubMed

Cancer Lett. 2004 Jun 8;209(1):1-6 PubMed

J Clin Endocrinol Metab. 1999 Nov;84(11):4232-8 PubMed

Br J Cancer. 2000 Jan;82(2):315-22 PubMed

J Clin Endocrinol Metab. 2006 Sep;91(9):3667-70 PubMed

Endocr Rev. 2007 Dec;28(7):742-62 PubMed

Nat Genet. 2003 Jan;33(1):19-20 PubMed

J Clin Endocrinol Metab. 2004 Sep;89(9):4267-71 PubMed

Cancer. 1999 Jul 1;86(1):149-56 PubMed

Ann Surg. 2006 Nov;244(5):799-804 PubMed

Oncogene. 2003 Oct 9;22(44):6942-5 PubMed

Yonsei Med J. 2004 Oct 31;45(5):818-21 PubMed

Cancer Res. 2003 Apr 1;63(7):1454-7 PubMed

Eur J Cancer. 2005 Mar;41(5):816-21 PubMed

Cancer Res. 2003 Aug 1;63(15):4561-7 PubMed

Oncogene. 2003 Jul 17;22(29):4578-80 PubMed

Cancer. 2009 Mar 1;115(5):972-80 PubMed

Lab Invest. 2005 Sep;85(9):1065-75 PubMed

Nature. 2002 Jun 27;417(6892):949-54 PubMed

Virchows Arch. 2005 Jun;446(6):589-95 PubMed

J Clin Endocrinol Metab. 2005 Dec;90(12):6373-9 PubMed

J Clin Endocrinol Metab. 2004 Mar;89(3):1365-8 PubMed

Clin Endocrinol (Oxf). 2005 Oct;63(4):461-6 PubMed

J Proteome Res. 2007 Feb;6(2):469-79 PubMed

J Pathol. 1998 May;185(1):71-8 PubMed

Med Sci Monit. 2004 Jul;10(7):CR300-6 PubMed

J Clin Endocrinol Metab. 2003 Sep;88(9):4393-7 PubMed

Ann Surg. 2007 Sep;246(3):466-70; discussion 470-1 PubMed

J Clin Endocrinol Metab. 2007 Nov;92(11):4085-90 PubMed

Cancer. 2006 Feb 1;106(3):524-31 PubMed

Oncogene. 1996 Aug 15;13(4):687-93 PubMed

J Pathol. 2004 Feb;202(2):247-51 PubMed

Microenvironment‑driven resistance to B‑Raf inhibition in a melanoma patient is accompanied by broad changes of gene methylation and expression in distal fibroblasts

BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment

Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants

A 3-bp Deletion VK600-1E in the BRAF Gene Detected in a Young Woman with Papillary Thyroid Carcinoma

Association between BRAF V600E mutation and recurrence of papillary thyroid cancer

Cribriform adenocarcinoma of minor salivary glands may express galectin-3, cytokeratin 19, and HBME-1 and contains polymorphisms of RET and H-RAS proto-oncogenes